Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?
Dhaun
Neeraj
N
Webb
David J
DJ
D001794:Blood Pressure / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D019332:Endothelin-1 / Q000097:blood*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D007211:Indoles / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008954:Models, Biological; D011507:Proteinuria / Q000097:blood / Q000139:chemically induced; D011758:Pyrroles / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012083:Renin / Q000097:blood; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D019332:Endothelin-1; D007211:Indoles; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D020794:Receptor Protein-Tyrosine Kinases; D012083:Renin; D000077210:Sunitinib